Co­herus Bio­Sciences lays off 20% of staff, while an­timi­cro­bial biotech makes deep­er cuts

More lay­offs have hit the biotech in­dus­try this week, with Co­herus Bio­Sciences say­ing it let go about 60 em­ploy­ees and an an­timi­cro­bial drug de­vel­op­er part­ing ways with 30% of its staff.

The lay­offs at Co­herus, an im­muno-on­col­o­gy biotech and mak­er of biosim­i­lars, equate to rough­ly 20% of the 359 full-time and part-time em­ploy­ees it had at the end of 2022, all based in the US. The Red­wood City, CA biotech dis­closed the news in its quar­ter­ly up­date. In an SEC fil­ing, Co­herus said most of the lay­offs would go in­to ef­fect on Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER